PDF(Pubmed)
Abstract：
Y-box binding protein-1 (YB-1) is a proto-oncogenic protein associated with protein translation regulation. It plays a crucial role in the development and progression of triple-negative breast cancer (TNBC). In this study, we describe a promising approach to inhibit YB-1 using SU056, a small-molecule inhibitor. SU056 physically interacts with YB-1 and reduces its expression, which helps to restrain the progression of TNBC. Proteome profiling analysis indicates that the inhibition of YB-1 by SU056 can alter the proteins that regulate protein translation, an essential process for cancer cell growth. Preclinical studies on human cells, mice, and patient-derived xenograft tumor models show the effectiveness of SU056. Moreover, toxicological studies have shown that SU056 treatment and dosing are well tolerated without any adverse effects. Overall, our study provides a strong foundation for the further development of SU056 as a potential treatment option for patients with TNBC by targeting YB-1.
摘要：
Y盒结合蛋白-1（YB-1）是一种与蛋白质翻译调节相关的原癌基因蛋白。它在三阴性乳腺癌（TNBC）的发生发展中起着至关重要的作用。在这项研究中,我们描述了一种使用小分子抑制剂SU056抑制YB-1的有希望的方法。SU056与YB-1物理相互作用并减少其表达，这有助于抑制TNBC的进展。蛋白质组谱分析表明，SU056对YB-1的抑制可以改变调节蛋白质翻译的蛋白质，癌细胞生长的基本过程。人类细胞的临床前研究,老鼠,和患者来源的异种移植肿瘤模型显示了SU056的有效性。此外，毒理学研究表明，SU056治疗和给药耐受性良好，没有任何不良反应。总的来说,我们的研究为进一步开发SU056作为靶向YB-1治疗TNBC患者的潜在治疗选择奠定了坚实的基础.
